SNDX vs. NAMS, ARDX, GLPG, KROS, AGIO, PTGX, CPRX, EVO, HRMY, and AMPH
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include NewAmsterdam Pharma (NAMS), Ardelyx (ARDX), Galapagos (GLPG), Keros Therapeutics (KROS), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Evotec (EVO), Harmony Biosciences (HRMY), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Syndax Pharmaceuticals currently has a consensus target price of $34.42, suggesting a potential upside of 69.62%. NewAmsterdam Pharma has a consensus target price of $33.25, suggesting a potential upside of 65.51%. Given Syndax Pharmaceuticals' higher possible upside, equities analysts plainly believe Syndax Pharmaceuticals is more favorable than NewAmsterdam Pharma.
NewAmsterdam Pharma's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.
Syndax Pharmaceuticals received 355 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 64.73% of users gave Syndax Pharmaceuticals an outperform vote.
NewAmsterdam Pharma has lower revenue, but higher earnings than Syndax Pharmaceuticals.
In the previous week, Syndax Pharmaceuticals had 5 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 12 mentions for Syndax Pharmaceuticals and 7 mentions for NewAmsterdam Pharma. Syndax Pharmaceuticals' average media sentiment score of 0.69 beat NewAmsterdam Pharma's score of 0.39 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.
Syndax Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500.
Summary
NewAmsterdam Pharma beats Syndax Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
